[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"solid-pancreatic-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:solid-pancreatic-neoplasms":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100504403","plasma-cfdna-fragmentomics-for-early-pnet-detection-and-differential-diagnosis-of-solid-pancreatic-tumors-100504403",false,"NCT05847855","Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors","A Prospective Study of Plasma Cell-free DNA Fragmentomics for Early Detection of Pancreatic Neuroendocrine Tumors and Differential Diagnosis of Solid Pancreatic Tumors","Inclusion Criteria:\n\n* Age 18 and above, regardless of gender;\n* Histopathological diagnosis with non-functional pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;\n* Not receiving any anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;\n* No obvious surgical contraindications;\n* Able to comply with research plans, follow-up plans, and other protocol requirements;\n* Voluntary participation and signed informed consent.\n\nExclusion Criteria:\n\n* Pathological diagnosis was not pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;\n* Currently diagnosed with other types of tumors or any cancer history;\n* Diagnosed with familial syndromes;\n* Receiving anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;\n* Ongoing fever or recipient of anti-inflammation therapy within 14 days prior to study blood draw;\n* Recipient of blood transfusion within 30 days prior to study blood draw;\n* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;\n* Poor health condition and not suitable for blood draw;\n* Any other disease\u002Fcondition deemed not suitable for study enrollment by researcher.",true,"ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","This prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors and differential diagnosis of solid pancreatic tumors.",[25,26],"Pancreatic Neuroendocrine Tumor","Solid Pancreatic Neoplasms",[28,29,30,31,32],"Pancreatic neuroendocrine tumor","cell-free DNA","fragmentomics","early detection","Solid pancreatic neoplasms","RECRUITING","2026-03-23",{"date":36,"type":37},"2026-03-25","ACTUAL",{"date":39,"type":37},"2023-02-27",{"date":41,"type":21},"2026-06-30",{"name":43,"class":44},"Fudan University","OTHER",2]